View Older Stories View More Recent Stories

Sep 30, 2025 04:24PM Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 21, 2025 07:30AM Pyxis Oncology to Participate in September Investor and Industry Conferences
Aug 14, 2025 04:05PM Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
Jun 30, 2025 04:30PM Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2025 07:00AM Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
May 14, 2025 07:30AM Pyxis Oncology to Participate in Two Upcoming Investor Conferences
Apr 25, 2025 01:18PM Pyxis Oncology (PYXS) Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin
Apr 25, 2025 01:17PM Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
Apr 2, 2025 07:30AM Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Mar 25, 2025 04:30PM Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
Mar 18, 2025 07:30AM Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Mar 3, 2025 07:30AM Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
Feb 26, 2025 07:31AM Pyxis Oncology (PYXS) Granted FDA Fast Track Designation for PYX-201
Feb 26, 2025 07:30AM Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Feb 4, 2025 07:31AM Pyxis Oncology (PYXS) Initiates New PYX-201 Combination Trial
Feb 4, 2025 07:30AM Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
Dec 19, 2024 04:08PM Pyxis Oncology (PYXS) Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
Dec 19, 2024 04:08PM Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
Nov 20, 2024 04:05PM Pyxis Oncology (PYXS) Reports Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
Nov 20, 2024 04:05PM Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
Nov 12, 2024 07:30AM Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
Nov 11, 2024 07:00AM Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
Aug 29, 2024 07:30AM Pyxis Oncology to Participate in Two Upcoming Investor Conferences
Aug 14, 2024 04:05PM Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
Jul 29, 2024 08:00AM Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
Jun 28, 2024 04:30PM Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 10, 2024 06:33AM Pyxis Oncology (PYXS) Appoints Michael A. Metzger to its Board
May 30, 2024 07:30AM Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
May 14, 2024 07:30AM Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
May 9, 2024 07:30AM Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
Mar 28, 2024 04:30PM Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 27, 2024 07:30AM Pyxis Oncology (PYXS) Obtains $8 Million Payment for the Sale of Royalty Rights
Mar 27, 2024 07:30AM Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
Mar 21, 2024 07:30AM Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
Mar 7, 2024 04:30PM Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
Mar 5, 2024 04:45PM Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
Dec 29, 2023 04:30PM Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 28, 2023 07:11AM Pyxis Oncology (PYXS) Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
Nov 28, 2023 07:00AM Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
Nov 7, 2023 04:30PM Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
Sep 27, 2023 09:18AM Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
Aug 31, 2023 04:01PM Pyxis Oncology to Participate in Two Upcoming Investment Conferences
Aug 23, 2023 08:35AM Pyxis Oncology Successfully Completes Acquisition of Apexigen
Aug 11, 2023 07:00AM Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
Aug 1, 2023 04:01PM Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
Jun 30, 2023 05:00PM Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 30, 2023 08:32AM Pyxis Oncology (PYXS) Advances PYX-106 and PYX-201 Clinical Programs
May 30, 2023 08:30AM Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
May 24, 2023 06:45AM Pyxis Oncology (PYXS) to Acquire Apexigen (APGN) for $0.64/sh
May 24, 2023 06:45AM Pyxis Oncology to Acquire Apexigen
View More Recent Stories View Older Stories